Hypertension: uptitration with perindopril/amlodipine single-pill combination is safe and effective

  • Poulter NR & al.
  • Am J Cardiovasc Drugs
  • 28 Mar 2019

  • curated by Sarfaroj Khan
  • UK Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.


  • In mild-to-severe hypertension, all four incremental doses (3.5/2.5, 7/5, 14/5 and 14/10 mg) of the perindopril/amlodipine single-pill combination (SPC) showed significant improvement in blood pressure (BP) control, BP response and mean BP levels.
  • Overall BP-lowering effects with perindopril/amlodipine were similar to irbesartan/hydrochlorothiazide therapy.

Why this matters

  • Latest British guidelines recommend a renin-angiotensin system blocker plus a calcium channel blocker as the single optimal combination of drugs and this is one of the combinations ‘preferred’ in European guidance.

Study design

  • This study included 3270 patients with mild-to-severe hypertension who were randomly assigned to receive 4 incremental doses of perindopril/amlodipine SPC (n=1617) and irbesartan-based regimen (150, 150/12.5, 300/12.5 and 300/25 mg; n=1653).
  • Primary endpoint: proportion of patients with controlled BP at each uptitrated dose at 6 months.
  • Secondary endpoint: BP response (reduction in systolic and diastolic BP), mean BP levels, 24-hour ambulatory BP measurement (ABPM) and BP variability.
  • Funding: Servier.

Key results

  • BP control rates increased significantly from 21% to 30%, 37% and 42% with each increase in perindopril/amlodipine dose after 1, 2, 3 and 6 months, respectively (P<.005>
  • Similarly, BP response rates significantly increased from 47%, 62%, 68% and 73% at 1, 2, 3 and 6 months, respectively (P<.001>
  • After 6 months, mean BP level was reduced from 163.7/91.4 mmHg at baseline to 138.9/80.6 mmHg.
  • No significant difference was seen in 24-hour ABPM in patients who received irbesartan-based and perindopril/amlodipine therapy, but perindopril/amlodipine reduced BP variability vs irbesartan-based therapy.